Therapeutic agent for chronic obstructive pulmonary disease and method for treatment for chronic obstructive pulmonary disease with the same
This therapeutic agent for chronic obstructive pulmonary disease comprises, an active ingredient, at least one of a 7-aminoquinolinone derivative represented by the general formula (I): wherein R 1 represents a hydrogen atom or an alkyl group; R 2 and R 3 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group and an alkenyl group; and R 4 and R 5 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group, an alkenyl group and an aralkyl group, and its physiologically acceptable salt.
1. A method for treating chronic obstructive pulmonary disease in a warm-blooded animal in need thereof, which compromises orally or parenterally administering to the warm-blooded animal a therapeutic agent for chronic obstructive pulmonary disease comprising, as an active ingredient, a 7-aminoquinolinone derivative represented by the general formula (I):
wherein R 1 represents a methyl group; R 2 represents an octyl group; R 3 represents a hydrogen atom; R 4 represents a hydrogen atom; and R 5 represents a 3,5-dimethoxy-4-hydroxycinnamoyl group, and its physiologically acceptable salt,
wherein a dose as an amount of active ingredient is from 0.01 to 50 mg per day per 1 kg of body weight in the case of oral administration, the dose as the amount of active ingredient is from 0.01 to 10 mg per day per 1 kg of body weight in the case of parenteral administration.
2. The method for treating chronic obstructive pulmonary disease according to claim 1 , wherein the chronic obstructive pulmonary disease is chronic bronchitis.
3. The method for treating chronic obstructive pulmonary disease according to claim 1 , wherein the chronic obstructive pulmonary disease is pulmonary emphysema.
4. The method for treating chronic obstructive pulmonary disease according to claim 1 , wherein said therapeutic agent for chronic obstructive pulmonary disease is orally administered.
5. The method for treating chronic obstructive pulmonary disease according to claim 1 , wherein said therapeutic agent for chronic obstructive pulmonary disease is taken internally.
6. The method for treating chronic obstructive pulmonary disease according to claim 1 , wherein said therapeutic agent for chronic obstructive pulmonary disease is orally administered to treat pulmonary emphysema.
7. The method for treating chronic obstructive pulmonary disease according to claim 1 , wherein said therapeutic agent for chronic obstructive pulmonary disease is orally administrated to improve lung resistance.
8. The method for treating chronic obstructive pulmonary disease according to claim 1 , wherein said therapeutic agent for chronic obstructive pulmonary disease is parenterally administrated to inhibit infiltration of inflammatory cells into airway.
9. The method for treating chronic obstructive pulmonary disease according to claim 2 , wherein said therapeutic agent for chronic obstructive pulmonary disease is orally administrated to improve lung resistance.
10. The method for treating chronic obstructive pulmonary disease according to claim 2 , wherein said therapeutic agent for chronic obstructive pulmonary disease is orally administrated to improve residual volume.
11. The method for treating chronic obstructive pulmonary disease according to claim 2 , wherein said therapeutic agent for chronic obstructive pulmonary disease is parenterally administrated to inhibit infiltration of inflammatory cells into airway.
12. The method for treating chronic obstructive pulmonary disease according to claim 3 , wherein said therapeutic agent for chronic obstructive pulmonary disease is orally administrated to improve lung resistance.
13. The method for treating chronic obstructive pulmonary disease according to claim 3 , wherein said therapeutic agent for chronic obstructive pulmonary disease is orally administrated to improve residual volume.
14. The method for treating chronic obstructive pulmonary disease according to claim 3 , wherein said therapeutic agent for chronic obstructive pulmonary disease is parenterally administrated to inhibit infiltration of inflammatory cells into airway.